Artemisinin-induced delayed hemolysis after administration of artesunate and artesunate-amodiaquine in malaria-free Wistar rats

Titilope M. Dokunmu*, Chidinma L. Ahanonu, Oreoluwa O. Abegunde, Oladipupo A. Adeyemi

Biochemistry and Molecular Biology Unit, Biological Sciences Department, Covenant University, Ota, Ogun state, Nigeria

Abstract

Background: Hemolysis is common in malaria infection and during the course of treatment. Previous studies have reported delayed post-artemisinin hemolysis occurring in naive and immune individuals treated with parenteral or oral artemisinin-derivatives. This study aims to understand if delayed hemolysis occurs in the absence of malaria parasites and the underlying mechanisms for the hemolytic effects after administration of two antimalarial drugs to malaria-free Wistar rats. Methods: Forty animals were randomized into 5 groups of eight animals each; they received 4 mg/kg artesunate for 7 days (AS), 4 mg/kg artesunate plus 10mg/kg amodiaquine for 3 days (ASQ), 10mg/kg amodiaquine for 3 days (AQ), distilled water [normal control], (Control) and 1mg/kg phenylhydrazine for 1 day to induce hemolysis (PHZ) groups respectively. Packed cell volume (PCV), white blood cell differential count and serum haptoglobin (Hpt) levels were determined in all groups on day 4 and 18 to detect hemolysis. Mean values were compared using t-test and ANOVA with p values < 0.05 taken to be significantly different. Results: Post-treatment mean PCV on day 4 was significantly lower than day 18 in all groups except AS group which had similar PCV all through evaluation. Although AQ had lowest mean PCV on day 4, by day 18, mean PCV returned to normal and hpt levels was significantly higher than AS and ASQ groups (p < 0.001). Hpt level (mean ± sem) for AS, ASQ, AQ, and control on day 18 were: 18.67 ± 0.004, 50.66 ± 0.014, 73.06 ± 0.003, and 74.13 ± 0.032 mg/dl respectively (p < 0.0001). On day 18, AS and ASQ had significantly lower Hpt level compared to day 4 (p <0.001). No neutropenia was observed during the study. Conclusion: Artesunate induces delayed hemolysis in malaria-free animals possibly through an oxidative toxic effect on the red blood cell membrane. Delayed post-treatment hemolysis was not observed with artesunate-amodiaquine or amodiaquine alone.
Keywords

Delayed hemolysis, Artemisinin, Antimalarial, Drug-induced hemolysis

Introduction

Hemolysis, the immature destruction of red blood cells (RBC) at a rate that exceeds production of the RBC, commonly occurs in malaria infection. The causes of hemolysis is multifactorial, it may be a consequence of merozoite release from red blood cells, suppression of erythropoiesis by cytokines which are released along with, nutritional deficiencies, immunity, hemoglobinopathies or oxidative effects of drugs. In the food vacuole of malaria parasite, heme increases the activation of the endoperoxide moiety of the drug (Meshnick, 1996) to generate reactive oxygen species, glutathione peroxidase and malondialdehyde which causes damage to the parasite membranes and proteins (Meshnick et al., 1989; Scott et al., 1989). The resulting degree of hemolysis depends on the duration and course of malaria infection (Price et al., 2001; Yeo et al., 2009).

Artemisinin based combination treatments are the most rapidly acting and effective antimalarials for treatment of falciparum malaria (WHO, 2014). Artemisinin drugs are known to act by inducing oxidative stress after activation of the peroxide bridge which generates reactive metabolites (Meshnick, 1994); this is their major mechanism of killing malaria parasite. Despite generating oxidative radicals, artemisinins are known to conserve the red blood cells, this is demonstrable by moderate falls in hematocrit (Price et al., 2001; Obonyo et al., 2007; Gbotosho et al., 2014) and presence of once infected red blood cells in circulation after parasite clearance (Angus et al., 1997; Chotivanich et al., 2000; Newton et al., 2001). The red cell conservation by artemisinin drugs is however transient because the erythrocytes are eventually destroyed by the spleen leading to the “delayed post-artemisinin hemolytic” syndrome (DPAH).

Delayed hemolysis was first recognized after parenteral artesunate in naïve patients, studies have also reported delayed hemolytic anemia after administration of oral artemisinin derivatives in immune and non-immune subjects with severe malaria or hyperparasitemia (WHO, 2013; 2014; CDC, 2014; Jauregui Berry et al., 2014; Rehman et al., 2014; Molta et al., 2003). Different hypothesis have been proposed to explain the underlying cause of hemolysis after artemisinin treatment, however the hypothesis that pitted erythrocytes are destroyed during recovery best explains post-artesunate delayed hemolysis after
treatment of malaria infection (Jauregui Berrey et al., 2014). Hemolysis may occur after treatment with different classes of antimalarials (Price et al., 2001; Obonyo et al., 2001; Sumbele et al., 2010; Sowunmi et al., 2009), however studies have not reported delayed post-treatment hemolysis occurring with antimalarials other than artemisinin derivatives.

This study aims to better understand the mechanism of post-delayed hemolytic effects of artemisinin and a commonly used partner drug – amodiaquine. This study evaluates post-artesunate or ACTs delayed hemolytic effects in uninfected animal model, providing a clear understanding of the mechanism of delayed hemolysis after antimalarial treatment.

**Materials - Methods**

**Study design**

Forty female albino rats were weighed and divided randomly into five groups of eight animals each. There were 4 treatment groups (3 groups received antimalarials, 1 group received a known hemolytic drug) and one untreated group (control). Treatment outcomes were compared within treatment groups or with positive or normal control group.

**Drug treatment**

Two commercially available antimalarials were purchased and used for the study; 200mg base amodiaquine (Camoquin®, Pfizer, USA) and 50mg artesunate (Artesunat®, Mekophar, Vietnam) and were crushed and dissolved in distilled water. Standard doses of the drugs were administered based on weight of the animals and given orally using cannula. Animals in group 1 received 4mg/kg body weight artesunate for 7 days (AS), group 2 received 10mg/kg amodiaquine (AQ) for 3 days, group 3 received 4mg/kg artesunate plus 10mg/kg amodiaquine (ASQ) for 3 days, group 4 received distilled water and served as normal control (Control) and group 5 received 1ml/kg phenylhydrazine for 1 day and served as positive control for hemolysis (PHZ).

**Animals**

The animals were purchased and housed separately per group; they were kept at room temperature in the animal house to acclimatize for one week. They were fed animal feeds *ad-libitum* and allowed free movement. All the animal experiments and handling were carried out following the standard ethics for Animal studies.
Laboratory tests

Blood samples for hematological tests were collected by pricking the tail of the rat on day 0, 4 or 8 and 18 after treatment. The blood was collected in microhematocrit tubes and centrifuged at 12,000 x g for 5 minutes to determine packed cell volume (PCV). Post-treatment, half of the animals were sacrificed on the day of test; 3mls blood was collected through cardiac puncture under mild anesthesia using diethyl ether. The blood samples were collected into heparinized tubes or plain bottles and centrifuged at 12,000 x g for 15mins to obtain the serum and plasma. Blood for reticulocyte and white blood cell count was diluted with normal saline and fixed with methanol before counting.

They were stained with Leishman, and counted against 1000 white blood cells using Naubauer hemocytometer under the microscope at magnification of x100. Differential count of the white blood cells was determined by absolute neutrophil, basophil, eosinophil, monocyte and reticulocytes count, thereafter the percentage of each was calculated from a total of 100 cells counted. Haptoglobin test was done on day 4 in half of the animals and on day 18 in the other half. Hemolysis was induced in group 5 by oral administration of 1ml/kg body weight of phenylhydrazine intravenously on day 4. This served as positive control for hemolysis.

Haptoglobin assay

Rat haptoglobin (Hpt) level was assayed using the biotin labelled ELISA kit (EASTBIOPHARM®) and was carried out according to manufacturer’s instructions as follows. Serum (40ul) sample was added to each Hpt pre-coated well, incubated with anti-Hpt antibody labeled with biotin or streptavidin-HRP at 37°C for 60 minutes. The reaction was terminated using chromogen reagent and absorbance was read on a microplate reader at 450nm wavelength and compared with standard.

Hematological evaluation

Hemolytic effects of drug treated groups were compared with normal control and positive control groups. Anemia was taken to be present if PCV value was <30% and hemolysis was present if Hpt level is very low or similar to that of positive control. Overall neutrophil counts lower than 100 (against 1000 WBC) was taken to indicate neutropenia. At recovery phase, hematological values in drug treated groups were compared with control groups to determine extent of hemolysis and recovery.

Statistical Analysis

The data was analyzed using the SPSS software version 16 (SPSS Inc., Chicago, USA). Graphs were done using excel or Graph pad prism software (Graphpad version 4.0, 1999). Values are reported as mean values ± standard error of mean
or proportions. Mean values were compared using t-test or ANOVA, followed by Duncan’s multiple range test, proportions were compared using chi-square test or fisher exact test, the level of significance was set at $p<0.05$.

## Results

Before treatment, the weight range of the animals was between 170-250 g. The average weight of all animals on day 0 was 201.25 g and mean packed cell volume on day 0 was 48.1%. Severe hemolytic effects were not recorded in any animal.

### Packed cell volume

Packed cell volume in all but 1 animal was >30% prior to treatment, this one animal was excluded from evaluation. Following treatment, anemia was not recorded in any animal. Table 1 shows the hematological outcomes in all groups. Post-treatment and recovery PCV values were similar in AS group ($p = 0.10$). In ASQ and AQ groups, there was 28-38% fall in PCV by day 4 after treatment, this was significantly lower than PHZ group, however mean PCV on day 18 was significantly higher than day 4 ($p < 0.03$). In PHZ group, PCV continued to decline until day 18 (Fig. 1). In ASQ and AQ, mean PCV on day 4 was significantly lower than other treatment groups ($p < 0.0001$) (Fig. 1). After completion of treatment, mean PCV was significantly higher in AS than ASQ or AQ ($p < 0.0001$). PCV on day 18 in all groups was similar, but significantly higher than PHZ ($p < 0.001$) indicating full recovery from the moderate and non-severe hemolytic effects of the antimalarials.

![Figure 1. Mean packed cell volume in artesunate (AS), artesunate-amodiaquine (ASQ), amodiaquine (AQ), and control (CTRL) groups of malaria-free rats.](image)
### Table 1. Hematological profiles of treated animals during the study

<table>
<thead>
<tr>
<th></th>
<th>AS</th>
<th>ASQ</th>
<th>AQ</th>
<th>PHZ</th>
<th>Control</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D0</strong>&lt;br&gt;Mean ± sd (%)</td>
<td>52.4 ± 4.15</td>
<td>46.75 ± 1.70</td>
<td>47.25 ± 3.40</td>
<td>48.6 ± 4.08</td>
<td>46.2 ± 1.25</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>After treatment</strong>&lt;br&gt;Mean ± sd (%)</td>
<td>52.5 ± 1.68 §</td>
<td>36.0 ± 4.24*</td>
<td>35.5 ± 3.50*</td>
<td>45.0 ± 7.07</td>
<td>46.0 ± 6.25</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>At recovery</strong>&lt;br&gt;Mean ± sd (%)</td>
<td>54.5 ± 0.71</td>
<td>59.5 ± 6.36</td>
<td>58.0 ± 7.01</td>
<td>40.0 ± 4.24**</td>
<td>60.0 ± 5.25</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Neutrophil count D4 (%)</strong></td>
<td>17</td>
<td>16</td>
<td>18</td>
<td>ND</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td><strong>Neutrophil count D18 (%)</strong></td>
<td>17</td>
<td>19</td>
<td>15</td>
<td>ND</td>
<td>13</td>
<td>-</td>
</tr>
<tr>
<td><strong>P value</strong>&lt;br&gt;(within group)</td>
<td>0.10</td>
<td>0.0001</td>
<td>0.001</td>
<td>0.56</td>
<td>0.003</td>
<td>-</td>
</tr>
</tbody>
</table>

* Significantly lower than other treatment groups after treatment, ** significantly lower than other treatment groups at recovery, § evaluation done on D8, ND – not done

### Haptoglobin level

In AS group, mean Hpt level on day 8 was 67.73 mg/dl, this was significantly higher than Hpt level on day 18 (18.67 mg/dl), p < 0.0001. In ASQ, mean Hpt level on day 4 (73.06 mg/dl) was significantly higher than day 18 (50.66 ± 0.013 mg/dl), p = 0.001 while in AQ group, mean haptoglobin level was significantly lower on day 4 (58.13mg/dl) than day 18 (73.46 mg/dl), p = 0.01. All treatment groups were compared with control at the recovery phase to determine delayed hemolysis. Hpt level (mean ± sem) for AS, ASQ, AQ, and control on day 18 were: 18.67 ± 0.004 (n = 2), 50.66 ± 0.014 (n = 4), 73.06 ± 0.003 (n = 4), and 74.13 ± 0.032 mg/dl (n = 3), respectively. There was a significantly lower Hpt level in AS and ASQ groups compared to AQ or control groups on day 18 (p <0.05) (Fig. 2).

### White Blood Cell Differential Count

Total white blood cell (WBC) count on day 0 was within normal range (5 x 10⁹/mm³), this was similar in all groups at baseline, after treatment (day 4) and during recovery (day 18). Neutrophils were compared within and between groups to determine if neutropenia occurred following treatment and during recovery. Neutropenia and agranulocytosis was not observed. In AS and AQ groups, no significant difference was observed between day 4 and day 18 (p = 0.703). Overall, there was no significant difference in differential count observed in all groups compared to PHZ group.
Discussion

The recent reports of delayed post-artemisinin hemolysis have brought to light the unrecognized burden of drug-induced hemolysis occurring especially after treatment of infections. Studies have reported immunosuppressive or inhibition of erythropoiesis (Yang et al., 2005; Wang et al., 2007; Finaurini et al., 2010), and other adverse effects of artemisinin derivatives both in the presence or absence of malaria parasites including hemolytic effects (Gu et al., 1986; Orjih, 1996; Garba and Ubom, 2005; Zhou et al., 2005; Anaba et al., 2012; Alzoubi et al., 2014; Lee et al., 2015; Kurth et al., 2016), many of which appear to be non-severe. The mechanism for inducing delayed post-artemisinin hemolysis when administered as monotherapy or co-administered with a partner drug such as amodiaquine remains to be understood. Artemisinin-based combination treatments (ACTs) remains the preferred first-line and safe treatment of falciparum malaria because of its rapid clearance of parasitemia, and reduction of chances of deaths in cases of severe malaria (Sinclair et al., 2012).

In the present study, animals in AQ and ASQ groups recovered from the hemolytic effects of all drug treatment. Packed cell volume and differential count by day 18 were similar compared to untreated animals. The lowest PCV values recorded on day 4 (after treatment) is a well explained phenomenon of drug induced hemolysis (Price et al., 2001; Sowunmi et al., 2009; Obonyo et al., 2007). This lends support to findings from other studies reporting decrease in hematocrit level after treatment with ACTs (Price et al., 2001; Omotuyi et al., 2008; Rolling et al., 2013; Gbotosho et al., 2014).
After completion of treatment, drug-attributable fall in hematocrit is common, this decline in hematocrit is attributable to the hemolytic effects of longer acting antimalarials (Price et al., 2001; Obonyo et al., 2007; Sowunmi et al., 2009). Haptoglobin is known to facilitate the removal of hemoglobin from the extravascular compartment via the CD163 macrophage scavenger receptor and is usually present in the presence of inflammation, or inflammatory diseases, or hemolysis to block hemoglobin-induced oxidative damage by forming haptoglobin-hemoglobin complex with decreased level reported in patients with acute inflammatory disease or hemolysis (Giffen et al., 2003; Rolling et al., 2013). Reduced serum haptoglobin observed in AS group on day 18 shows hemolysis occurred in the absence of malaria infection, although PCV level appeared normal.

Surprisingly, delayed hemolysis did not occur in ASQ group, this could have been masked by the effects of amodiaquine in the combination. In the absence of malaria parasites, free iron bioactivation of the endoperoxide bridge of artemisinin drugs can be used to modulate its effects (Meshnick et al., 1989; 1993; Meshnick, 1996; Krishna et al., 2004; Muhia et al., 1994; Meshnick, 1996; Tangnitipong et al., 2012; Conran, 2014). Delayed hemolysis in AS group follows a pattern similar to that reported in malaria infected persons (Eder et al., 2012; WHO, 2013; Arguin et al., 2014; Conran, 2014; Jauréguierry et al., 2014; Rehman et al., 2014; Chavada et al., 2015; Boillat et al., 2015; Lee et al., 2015; Rolling et al., 2015; Kurth et al., 2016), although no anemia was recorded throughout this study.

The mechanism of delayed hemolysis occurring in the absence of malaria parasite is likely due to toxic effects of artemisinin owing to generation of oxidative radicals. This can result in suppression of erythropoiesis (Yang et al., 2005; Wang et al., 2007; Finaurini et al., 2010) and toxicity of the red cell membrane through generation of reactive species which induce oxidative stress causing lipid peroxidation, glutathione oxidation and oxidation of membrane protein thiols (Scott et al., 1989; Meshnick, 1996). Drug-induced oxidative stress worsens hemolysis in the presence of hemoglobinopathies or inadequate protection by the antioxidant defense system of the red blood cells which is often overwhelmed in disease states such as malaria. In the absence of the protective enzyme glucose-6-phosphate dehydrogenase; which maintains the supply of reduced glutathione used to mop up free radicals, oxidative damage of the vascular epithelium occurs (Ruwende and Hill, 1998; Jollow and McMillan, 2001; Beutler et al., 2007; Chikezie et al., 2010; Vickers et al., 2010; Chikezie, 2014). In this study, G6PD deficiency or other hemoglobinopathies cannot be implicated.

Indeed studies have shown that oxidative stress precedes hemolysis of the red blood cells (Jollow and McMillan, 2001; Jeney et al., 2002) following a similar mechanism in both human and rats when exposed to highly oxidative compounds (Vickers et al., 2010). Shortened survival and removal of pitted erythrocytes explains only part of hemolysis in presence of malaria infection.
(Arguin et al., 2014; Jaureguiiberry et al., 2014; Rolling et al., 2015; Kurth et al., 2016), unparasitized red blood cells are also cleared (Newton et al., 2001). Increased splenic clearance and lysis of the erythrocytes is also attributed to altered symmetry of phospholipid layer and reduced red cell deformability due to membrane rigidity caused by merozite invasion (Pasvol et al., 1992; Dorndorp et al., 2001; Cooke et al., 2004; Park et al., 2008; Nuchsongsin et al., 2008).

In this study, the haptoglobin levels in all groups were moderately low by day 4, indicating potent hemolytic effect of both artesunate and amodiaquie. Clark et al. (1991) indicated that nitric oxide production increases in a state of infection such as malaria leading to poor deformability of red blood cells membrane. Free hemoglobin also depletes nitric oxide and increases oxidative inflammatory process. The nitric oxide is thought to inhibit Na+/K+ ATPase and causing oxidation of lipids in the red blood cell membrane through generation of peroxynitrate – a highly potent oxidant (Yeo et al., 2009). Most antimalarials reduce the deformability of the red blood cell membrane which makes the red cell rigid and unable to pass through the microcirculatory bed of the spleen, thus they are marked for splenic clearance (Dondorp et al., 2004).

Drug induced hemolysis can be easily implicated in a case of multiple drug intake, because hemolysis could be triggered via immune complex formation with the drugs on RBC surface or auto-antibody production. In humans, other possible causes of hemolysis include genetic susceptibility such as polymorphisms in drug metabolizing enzymes – CYP2A6 (Roederer et al., 2011), hemoglobinopathies such G-6-P-D deficiency which is common in malaria endemic areas (Price et al., 2001; Beutler et al., 2007; Van Malderen et al., 2012; Howes et al., 2012) and suppressed erythropoiesis after administration of artemisinin, in the presence of other hemolytic factors such as malaria parasite, it would result in anemia as seen in hyperparasitemic individuals.

The hypothesis that explains that post-artemisinin delayed hemolysis after treatment of malaria infection is attributable to eventual destruction of pitted erythrocytes which have a shortened lifespan (Clark, 2013; WHO, 2013; Arguin et al., 2014) could also explain the case with malaria-free animals in which case exposure to artemisinin drugs cause oxidative stress on the red cell membrane, thus a reduced lifespan or clearance by the spleen. Haptoglobin levels in the experimental animals indicate that hemolysis occurred during treatment in all groups but was more pronounced on day 18 in AS group. Although Hpt level observed in ASQ group was low, it was not as low as in artesunate-treated animals on day 18. Only 2 animals were evaluable in AS group on day 18, this may have accounted for a skewed value recorded for the group.

Amodiaquine is implicated as a cause of neutropenia, which is characterized by a decrease in granular white blood cells after prolonged use for prophylaxis (Olliaro and Mussano, 2003). Our findings are in consonance with other reported animals studies (Omotuyi et al., 2008) and that observed in human treated with amodiaquine, they showed normal limits of hematological profile with no
agranulocytosis (Molta et al., 2003). Artesunate have been previously reported to be associated with neutropenia at doses higher than doses administered in our study (Bethell et al., 2010), however neutropenia was not observed with AS, ASQ or AQ during the study. This study lends support to a case report of artemesunate induced auto-immune post-treatment delayed hemolysis, although this occurred in a malaria patient (Raffray et al., 2014).

Limitations of the study

Artesunate treatment was given for 7 days following recommendation for artemesunate monotherapy while other treatments were administered for 3 days. This study did not evaluate delayed hemolysis after 3 days administration of artemesunate to see if the outcome will differ from the reported result. Other antimalarial drug combinations were not evaluated for this study. Comparison was done in half of the animals in each group sacrificed after treatment and the remaining half at the end of the study. Thus these data were taken to be representative of the hemolytic effects occurring in individual animals. It is not known if this is the case. Lactate dehydrogenase assay was not done and no malaria infected group was evaluated along with the study groups, this group would have shown hemolysis during untreated malaria infection in mice.

Conclusion

Hemolysis occurred with all treatment in the absence of malaria parasites but rather occurred late; during recovery in AS and ASQ groups, PCV levels did not indicate hemolysis, > 30% anemia cut off but hpt levels were lower. This study reports that delayed post-artemisinin hemolysis can also occur in the absence of malaria parasites possibly through an oxidative toxic effect on the red blood cell membrane. There was no delayed hemolysis occurring after amodiaquine administration, rather hemolysis occurred immediately after completion of treatment.
Abbreviations

RBC: red blood cells
PCV: packed cell volume
ELISA: enzyme-linked immunosorbent assay
G6PD: glucose-6-phosphate dehydrogenase
Hpt: haptoglobin
AS: artesunate
AQ: amodiaquine
ASQ: amodiaquine-artesunate
ACTs: artemisinin-based combination treatment.

Acknowledgements

We thank the Management of Covenant University and Biological Sciences Department for their support during the conduct of the reported study.

Author contribution

TMD designed the study and wrote the manuscript, AA carried out the laboratory evaluation, all authors participated in the conduct, analysis and contributed to the success of the study.
References


Center for Disease Control (2014). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria worldwide, 2010-2012. MMWR 63, 753-755.


Chikezie, P. C., Uwakwe, A. A., and Monaco, C. C. (2010). Comparative osmotic fragility of three erythrocyte genotypes (HbAA , HbAS and HbSS) of male participants administered with five antimalarial drugs 4, 57-64.


